Dihydropyridine calcium channel blocker — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the dihydropyridine calcium channel blocker class. 31 active patents protecting 3 drugs. First major cliff: 2038. Daily refresh.

3
Drugs in class
31
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators

Pfizer Inc. 16 patents Chiesi 9 patents

Cliff calendar — next 15 years

3
29
9
31
13
38
6
41

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Caduet
Amlodipine Besylate
 Pfizer Inc. 16 63 — 2029-10-05
Cleviprex
CLEVIDIPINE
 Chiesi 9 33 — 2031-10-10
Nimotop
NIMODIPINE
 — 6 65 — 2038-04-16

Most attackable patents

Patent Drug Type Vuln Expiry
10799487 Caduet method of use 75 2038-01-23
12186308 Nimotop method of use 75 2038-04-16
12440441 Caduet method of use 75 2041-02-24
12226528 Caduet method of use 75 2041-02-24
12005141 Caduet method of use 75 2041-02-24
11413277 Nimotop method of use 70 2038-04-16
11207306 Nimotop method of use 70 2038-04-16
11253474 Caduet method of use 70 2041-02-24
11458095 Caduet method of use 70 2041-02-24
11723866 Caduet method of use 70 2041-02-24

Strongest defences

Patent Drug Type Vuln Expiry
10010537 Cleviprex formulation 31 2031-10-10
10010537 Cleviprex formulation 31 2031-10-10
11103490 Cleviprex formulation 31 2031-10-10
11103490 Cleviprex formulation 31 2031-10-10
10010537 Cleviprex formulation 31 2031-10-10
11103490 Cleviprex formulation 31 2031-10-10
8658676 Cleviprex formulation 36 2031-10-10
8658676 Cleviprex formulation 36 2031-10-10
8658676 Cleviprex formulation 36 2031-10-10
10350171 Caduet formulation 42 2038-06-14

Related